Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Hormonal therapy targeting androgen receptor (AR) is initially effective to treat prostate cancer (PCa), but it eventually fails. It has been hypothesized that cellular heterogeneity of PCa, consisting of AR+ luminal tumor cells and AR- neuroendocrine (NE) tumor cells, may contribute to therapy fail...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, Yinglu Zhou, Allen C. Gao, Qingfu Zhang, Daniel Taylor, Donghui Cheng, Suzette Farber-Katz, Rachid Karam, Tyler Landrith, Bing Li, Sitao Wu, Vickie Hsuan, Qing Yang, Hailiang Hu, Xufeng Chen, Melissa Flowers, Shannon J. McCall, John K. Lee, B. Smith, Jung Wook Park, Andrew S. Goldstein, Owen N. Witte, Qianben Wang, Matthew B. Rettig, Andrew J. Armstrong, Qing Cheng, Jiaoti Huang
Materyal Türü: Artigo
Dil:İngilizce
Baskı/Yayın Bilgisi: 2019
Online Erişim:https://doi.org/10.1126/scitranslmed.aax0428
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Internet

https://doi.org/10.1126/scitranslmed.aax0428

Benzer Materyaller